2013-05-14T12:41:12-05:00 2012-12-31 EISNERAMPER LLP 750 THIRD AVENUE NEW YORK NY 100172703 990 2012-01-01 134141945 THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH % % STEPHEN GRUBB - MJFF MICH 2125090995 GRAND CENTRAL STATION PO BOX 4777 Suite NEW YORK NY 101634777 JOANNE MARTZ 2125290995 2013-05-14 true 2129498700 2012 2016-03-07 17:11:31Z Todd Sherer GRAND CENTRAL STN PO BOX 4777 NY NY 101634777 122037106 false X www.michaeljfox.org X 2000 DE THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA. 29 28 84 17 18055 210 64970818 87327249 0 0 174041 25786 38514 183056 65183373 87536091 53857613 55079865 0 0 6906870 8458578 60000 0 5746832 4814498 6708348 65638981 70246791 -455608 17289300 95542240 105378503 74420395 66960964 21121845 38417539 X THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA. false false 62657563 55079865 TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE. 62657563 true true false false false false false false false false true false false false true true false true false true true true true true true false false true false true false false false false false false false false true false false false false true false false false true 114 0 true 84 true true true true CA false false false true true false false false false X 29 28 true false true false false false false true true false false true true true true true true true true false AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X STEPHEN GRUBB - MJFF 2125090995 GRAND CENTRAL STATION PO BOX 477 NEW YORK NY 101634777 X Michael J Fox 2.0 X 0 0 0 Robert W Shackleton 2.0 X X 0 0 0 George E Prescott 2.0 X X 0 0 0 Fred G Weiss 2.0 X X 0 0 0 Holly S Andersen MD 2.0 X 0 0 0 Eva Andersson-Dubin MD 2.0 X 0 0 0 Jon Brooks 2.0 X 0 0 0 Mark Booth 2.0 X 0 0 0 Barry J Cohen 2.0 X 0 0 0 Donny Deutsch 2.0 X 0 0 0 David Einhorn 2.0 X 0 0 0 Karen Finerman 2.0 X 0 0 0 Nelle Fortenberry 2.0 X 0 0 0 Albert B Glickman 2.0 X 0 0 0 David Golub 2.0 X 0 0 0 Mark L Hart III 2.0 X 0 0 0 Skip Irving 2.0 X 0 0 0 Edward Kalikow 2.0 X 0 0 0 Katheen Kennedy 2.0 X 0 0 0 Amar Kuchinad 2.0 X 0 0 0 Edwin A Levy 2.0 X 0 0 0 Marc S Lipschultz 2.0 X 0 0 0 Douglas I Ostrover 2.0 X 0 0 0 Tracy Pollan 2.0 X 0 0 0 Ryan Reynolds 2.0 X 0 0 0 Frederick E Rowe Jr 2.0 X 0 0 0 Lily Safra 2.0 X 0 0 0 Curtis Schenker 2.0 X 0 0 0 George Whelen 2.0 0.0 X 0 0 0 Todd Sherer 40.0 X 445616 0 26090 Joanne Martz 40.0 X 295473 0 20048 Deborah W Brooks 40.0 X 510660 0 26090 Sohini Chowdhury 40.0 X 210396 0 12452 Sheila Kelly 40.0 X 184863 0 11685 Holly Teichholtz 40.0 X 145286 0 16907 Brian K Fiske 40.0 X 186700 0 17935 Mark A Frasier 40.0 X 177852 0 5335 Alison Urkowitz 40.0 X 145290 0 10499 Laxmi Wordham 40.0 X 230440 0 25503 2532576 0 172544 18 false true false RUDER FINN INC 301 E 57TH STREET NEW YORK NY 10022 CONSULTING 198726 1 4823361 82503888 33493293 87327249 0 24221 24221 0 0 161299 161299 0 161299 161299 33562803 33561238 1565 1565 1565 913395 4529802 913395 0 0 44887 26382 18055 18055 MISCELLANEOUS REVENUE 900099 3702 3702 3702 87536091 18055 190787 37825367 37825367 0 17254498 17254498 0 1647008 807034 263521 576453 0 5525647 2709020 863425 1953202 188491 95280 28151 65060 609410 266543 110539 232328 488022 242038 72573 173411 0 108454 98250 731 9473 37662 37662 0 0 0 644425 411358 27751 205316 155901 68519 87382 809810 362312 48725 398773 407580 188218 18941 200421 0 1461819 730941 225757 505121 393081 126021 15094 251966 0 1059786 1059786 56420 56420 0 668503 317027 50375 301101 67055 54795 3013 9247 CREDIT CARD & BROKERAGE FEES 310526 326 15603 294597 OTHER SPECIAL EVENTS EXPENSE 209094 209094 DONATION PROCESSING 78827 78827 MARATHON RUNNER FEES 178983 178983 60422 40230 4115 16077 70246791 62657563 1842396 5746832 104 326 80371171 85393127 12027926 15199335 0 0 0 0 0 0 0 0 17847 19190 303256 312174 3832472 1688083 653423 2144389 1339815 1478589 0 0 0 0 0 0 828698 831373 95542240 105378503 1590225 2186550 56245521 62405623 14898701 0 0 0 0 0 0 0 0 0 1000196 1150196 685752 1218595 74420395 66960964 X 5774290 18533026 15347555 19884513 0 0 21121845 38417539 95542240 105378503 17289300 6394 X false true X true false X 42077867 51259577 57125384 64970818 87327249 302760895 0 0 42077867 51259577 57125384 64970818 87327249 302760895 140078581 162682314 744930 157415 232554 42326 24221 1201446 0 25682 15213 34177 38514 21757 135343 304097684 0.53497 0.59094 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1692761 407395 1285366 1887019 1069253 817766 252692 211435 41257 2144389 0 DEFERRED RENT 897274 DUE TO MJFF CANADA 105926 INTEREST PAYABLE 215395 1218595 X 87836044 6394 293559 299953 87536091 87536091 70540350 293559 293559 70246791 70246791 Schedule D, Page 3, Question 2: ASC 740-10-05 Footnote The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") Topic 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC Topic 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. Nonetheless, because of Foundation's general tax-exempt status, ASC Topic 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements. RECONCILIATION OF REVENUE AND EXPENSES SCHEDULE D, PARTS XII/XIII, LINES 2D, PAGE 4 AMOUNTS REPRESENT REVENUES AND EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY. true East Asia and the Pacific Grantmaking 1535455 North America Grantmaking 4400327 Europe (Including Iceland and Greenland) Grantmaking 10285793 Middle East and North Africa Grantmaking 946623 South America Grantmaking 86300 17254498 17254498 Europe (Including Iceland and Greenland) Xenon inhalation to reduce L-DOPA-induced dyskinesia 461577 North America Development of a non-human primate model of Parkinson's disease alpha-synucleinopathy 502882 Europe (Including Iceland and Greenland) Modulation of the CD40/CD40-Ligand Neuroinflammation Pathway in Parkinson's Mouse Models 74966 Europe (Including Iceland and Greenland) Development of an HTS assay to break the alpha- synuclein-glucocerebrosidase feedback loop 74250 Europe (Including Iceland and Greenland) Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein 947290 Europe (Including Iceland and Greenland) Enhanced CNS dopamine availability, prolonged activity and improved dyskinesia profile after administration of selectively deuterated L-DOPA 400000 East Asia and the Pacific Is the xenomitochondrial mouse an 'ideal' PD model? 36726 North America Mechanisms of Parkin Recruitment and Mitophagy 199990 North America A Two-dose Active Comparator, Randomized Cross- over Phase I Trial to Examine the Single Dose Pharmacokinetic Profile of Sublingual Administered APL-130277 as compared to APOKYN in Healthy Volunteers 947925 East Asia and the Pacific Collaborative validation of oxidized DJ-1 antibodies for PD biomarker study 203655 Europe (Including Iceland and Greenland) In vivo characterization of helper-dependent adenoviral vectors expressing human LRRK2 112163 Europe (Including Iceland and Greenland) Regulation of LRRK2 Activity and Toxicity by Nitrosative Stress and S-Nitrosylation: Implications for Idiopathic Parkinson's Disease 133474 Europe (Including Iceland and Greenland) Novel PD Tools: Generation of Post- translationally Modified Alpha-synuclein 233526 Europe (Including Iceland and Greenland) VPS35 as a Novel Target for Parkinson's Disease 249806 Europe (Including Iceland and Greenland) Investigation of the mechanisms involved in a-synuclein secretion in vivo 150000 East Asia and the Pacific Validation of ATP13a2/PARK9 as a Target to Reduce Neurodegeneration Induced by Alpha-Synuclein 249657 Europe (Including Iceland and Greenland) Enhancing PD symptom improvement and decreasing adverse event incidence from L-DOPA therapy by improving L-DOPA bioavailability and consistency of absorption through co-administration of the Motilin agonist, GSK962040 78410 Europe (Including Iceland and Greenland) Anti-parkinson and anti-dyskinetic efficacy studies of HE3286 in a MPTP non-human primate model for Parkinson's disease 431528 Europe (Including Iceland and Greenland) Protein Interaction network analysis and pathway modeling for LRRK2 1499839 Europe (Including Iceland and Greenland) Intestinal and nasal microbiota of patients with idiopathic Parkinson's disease 75000 Europe (Including Iceland and Greenland) PPMI 2012: RBD Core Support for Prodromal PPMI (P-PPMI) in 2013 130000 Europe (Including Iceland and Greenland) PPMI 2012: Cognitive Categorization Ancillary Study 14063 Europe (Including Iceland and Greenland) Is PD a low-grade inflammatory bowel disease? 52910 Europe (Including Iceland and Greenland) IMD-026259 - An Innovative Drug for Disease- Modifying Treatment of Parkinson's Disease 499989 Europe (Including Iceland and Greenland) Cognitive phenotypes in Parkinson's disease: anatomical and functional correlates 366025 Europe (Including Iceland and Greenland) The role of mGluR4 in the modulation of L-DOPA- induced motor performance and dyskinesia in a rat model of Parkinson's disease - 2012 35689 Europe (Including Iceland and Greenland) Neurotrophic and autophagic markers in Parkinson's disease: Implications for disease- modifying strategies 60000 Europe (Including Iceland and Greenland) Functional Integration of Grafted Human Induced Neuronal (iN) Cells in Parkinson's Disease 74951 Europe (Including Iceland and Greenland) Validation of IGF-1 as a neuroprotective agent in animal models of Parkinson?s disease 110000 Europe (Including Iceland and Greenland) Preclinical validation of a Nurr1 agonist for neuroprotection in Parkinson's disease 115500 Europe (Including Iceland and Greenland) Transfer of alpha-synuclein between the brain and peripheral organs 200000 Europe (Including Iceland and Greenland) Regulated GDNF gene therapy- a novel regulatory system based on protein degradation. 219451 Europe (Including Iceland and Greenland) PDGene Extension 58307 North America Stimulation of protein clearance mechanisms to improve clearance of toxic accumulations of alpha-synuclein protein in Parkinson's disease 75000 Europe (Including Iceland and Greenland) PPMI 2012: rsMRI Ancillary Study 9688 Europe (Including Iceland and Greenland) PPMI 2012: Cognitive Categorization Ancillary Study 11250 Europe (Including Iceland and Greenland) Laboratory phenotyping of Parkinson disease subjects using a multiplex approach 222023 Europe (Including Iceland and Greenland) PPMI Clinical Trial Site: Year Two 258781 Europe (Including Iceland and Greenland) The role of brain-specific PGC-1alpha isoforms in Parkinson Disease 75000 Europe (Including Iceland and Greenland) Clinical Coordination of LRRK2 Cohort Consortium- Supplement 24259 Europe (Including Iceland and Greenland) Lead optimization for a Parkinson's Disease therapeutic 399894 Europe (Including Iceland and Greenland) Trace amines and their metabolites as potential heraldic markers in Parkinson's disease 74986 Europe (Including Iceland and Greenland) PPMI Clinical Trial Site - SWEDD Amendment 59438 Europe (Including Iceland and Greenland) Ceruloplasmin deamidation in Parkinson's disease cerebrospinal fluid: gain of pro-adhesive function 73150 North America Sanofi Packaging and distribution project 19467 Middle East and North Africa LRRK2 Cohort Consortium Biorepository Agreement- Tel Aviv 946623 Europe (Including Iceland and Greenland) Attenuation of neuroinflammation by brain- targeted liposomal methylprednisolone (2B3-201) 75000 Europe (Including Iceland and Greenland) Characterizing region specific splice isoforms of LRRK2 124935 Europe (Including Iceland and Greenland) Cannabinoid CB2 receptors as a new target for the treatment of disease progression in Parkinson's disease: studies in LRRK2-transgenic mice 146258 North America Development of L-745,870, a selective D4 receptor antagonist, for the treatment of L-DOPA-induced dyskinesia 1086711 Europe (Including Iceland and Greenland) CD163+ macrophages as tools for neuroinflammatory modulation in Parkinson's disease 74745 Europe (Including Iceland and Greenland) Cleaved Cerebrospinal Fluid Proteins as Early Biomarkers for Detection of Parkinson's Disease 92640 North America Investigation of neuroinflammation in LRRK2 mutation carriers using positron emission tomography 249947 North America Imaging Neuroinflammation in LRRK2 Rat Models of Parkinson's Disease 296533 North America Pharmacological targeting of the 5-HT1, A2A and NMDA receptors: an integrative approach to dyskinesia 389400 South America Targeting the unfolded protein response transcription factor XBP1 to alleviate neurodegeneration triggered by alpha-synuclein. 86300 East Asia and the Pacific LRRK2 HD-AD5 Subcloning work 9468 East Asia and the Pacific Generation of phospho-PINK1 and phospho-Parkin Antibodies 18553 East Asia and the Pacific Combining mass spectrometry with genetic and pharmacological approaches to discover and validate LRRK2 substrates 1500057 Europe (Including Iceland and Greenland) Effects of recombinant CDNF protein in alpha- synuclein model of Parkinson's disease in rats 125000 Europe (Including Iceland and Greenland) PPMI 2012: Cognitive Categorization Ancillary Study 7969 Europe (Including Iceland and Greenland) PPMI 2012: rsMRI Ancillary Study 9688 East Asia and the Pacific Alpha synuclein as a major regulator of iron homeostasis 62203 North America LRRK2 regulates host response to microbial infections 250000 East Asia and the Pacific Evaluating a targeted cognitive training program for the treatment of Freezing of Gait 490663 North America A novel protease pathway in Parkinson's disease 74586 North America Biomarkers of PD risk in LRRK2 mutation carriers 466755 North America Validation of Sirtuin 3 as a Neuroprotective Target in Parkinson's Disease 250000 Europe (Including Iceland and Greenland) PPMI 2012: rsMRI Ancillary Study 9688 Europe (Including Iceland and Greenland) PPMI 2012: Cognitive Categorization Ancillary Study 15469 Europe (Including Iceland and Greenland) Polyglutamine repeats and Parkinson disease 74800 55 16 false false false false false false SCHEDULE F PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES: THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made. X X X X true Event Associates Inc Fundraising Consulting false 0 60000 0 0 60000 0 AL AK AZ AR CA CO CT FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI FUNNY THING 4225532 3520856 704676 0 0 447540 0 238355 18780 BREAKING PAR 614840 489652 125188 0 0 107838 0 17350 3 602825 519294 83531 0 3263 60858 0 16471 2940 5443197 4529802 913395 0 3263 616236 0 254826 39070 913395 true 23andMe Inc 2606 Bayshore Parkway Mountain View CA 94043 204857371 Public Sector 26400 Using external research experts to mine the 23andMe Parkinson's dataset 23andMe Inc 2606 Bayshore Parkway Mountain View CA 94043 204857371 Public Sector 291428 23andMe Blood Collection for the LRRK2 Consortium Acadia Pharmaceuticals 3911 Sorrento Valley Blvd San Diego CA 92121 061376651 Public Sector 322414 Development of Nurr1-RXR heterodimer selective agonists for Parkinson's disease Alnylam Pharmaceuticals 300 Third Street Cambridge MA 02142 770602661 Public Sector 25000 Therapeutic Development of siRNA Targeting Alpha-Synuclein Alnylam Pharmaceuticals 300 Third Street Cambridge MA 02142 770602661 Public Sector 162668 Therapeutic Development of siRNA Targeting Alpha-Synuclein Aperio Technologies 1360 Park Center Drive Vista CA 92081 330939292 Public Sector 10530 Aperio Website Hosting of Immunohistological Slides -LRRK2 Avanir Pharmaceuticals 20 Enterprise Orange CA 92121 330314804 Public Sector 569151 AVP-923 (dextromethorphan hydrobromide and quinidine sulfate) for levodopa induced dyskinesia in Parkinson's disease Banner Sun Health Research Institute 10515 W Santa Fe Drive Sun City AZ 85351 860768795 501(c)(3) 8438 PPMI 2012: Cognitive Categorization Ancillary Study Banner Sun Health Research Institute 10515 W Santa Fe Drive Sun City AZ 85351 860768795 501(c)(3) 15000 APDC Reviewer compensation Banner Sun Health Research Institute 10515 W Santa Fe Drive Sun City AZ 85351 860768795 501(c)(3) 50000 AV-133: PPMI Ancillary Study Baylor College of Medicine 6550 Fannin St Suite 1801 Houston TX 77030 741613878 501(c)(3) 9688 PPMI 2012: rsMRI Ancillary Baylor College of Medicine 6550 Fannin St Suite 1801 Houston TX 77030 741613878 501(c)(3) 13125 PPMI 2012: Cognitive Categorization Ancillary Study Baylor College of Medicine One Baylor Plaza Room 630E Houston TX 77030 741613878 501(c)(3) 45000 Generation of HD-Ad Type 5 LRRK2 expression vectors Baylor College of Medicine 6550 Fannin St Suite 1801 Houston TX 77030 741613878 501(c)(3) 50000 AV-133: PPMI Ancillary Study Beth Israel Deaconess Medical Center 330 Brookline Ave Room CLS-638 Boston MA 02445 042103881 501(c)(3) 75000 Irisin: A novel PGC-1alpha related target for neuroprotection in Parkinson's Disease Beth Israel Medical Center 10 Union Square East Suite 2Q New York NY 10003 135564934 501(c)(3) 142156 Planning Phase for LARRI Beth Israel Medical Center 10 Union Square East PACC Suite 5 New York NY 10003 135564934 501(c)(3) 509385 LRRK2 Mutations and Cancer Risk Biomer Technology 1047 Serpentine Lane Bldg 200 Pleasantown CA 94566 481286101 Public Sector 62000 Post-Translationally Modified Alpha-Synuclein: Generation and Ligation of modified Peptides to Alpha-Synuclein Protein Board of Regents of the University of Wisconsin 600 Highland Ave K4/7 CSC Madison WI 53792 396006492 501(c)(3) 79955 Characterization of vocalization and swallowing deficits in Pink1 knockout rats Boston University Robinson C-329 715 Albany St Boston MA 02118 042103545 501(c)(3) 12656 PPMI 2012: Cognitive Categorization Ancillary Study Boston University Robinson C-329 715 Albany St Boston MA 02118 042103545 501(c)(3) 137500 PPMI Clinical Trial Site: Year Two Boston University Robinson C-329 715 Albany St Boston MA 02118 042103545 501(c)(3) 150000 PPMI Clinical Trial Site: Year Three Boston University 72 East Concord St L-606B Boston MA 02118 042103545 501(c)(3) 274219 Clinical evaluation of LRRK2 inhibitors on inflammatory responses in Crohn's and Parkinson's diseases Brigham & Women's Hospital 65 Landsdowne Street Boston MA 02139 042312909 501(c)(3) 71607 Evaluation of PD-linked transcripts in PPMI City College of New York 1230 York Avenue Box 296 New York NY 10065 131624158 501(c)(3) 147301 The Role of CK2 in the development of L-DOPA- induced dyskinesia in Parkinson's disease Cleveland Clinic 9500 Euclid Avenue S-31 Cleveland OH 44195 340714585 501(c)(3) 9688 PPMI 2012: rsMRI Ancillary Study Cleveland Clinic 9500 Euclid Avenue S-31 Cleveland OH 44195 340714585 501(c)(3) 12188 PPMI 2012: Cognitive Categorization Ancillary Study Colorado State University 1680 Campus Delivery Fort Collins CO 805231680 846000545 501(c)(3) 112170 Targeting Nurr1 with novel diindolymethane compounds Columbia University 710 W168th St 3rd floor New York NY 10032 135598093 501(c)(3) 112500 BioFIND Clinical Trial Site- Columbia University Coriell Institute for Medical Research 403 Haddon Avenue Camden NJ 08103 210672684 501(c)(3) 5201 Collection, storage and distribution of MJFF samples from AVE8112 MAD study Coriell Institute for Medical Research 403 Haddon Avenue Camden NJ 08103 210672684 501(c)(3) 281480 23andme LRRK2 Cohort Consortium Biorepository Agreement Coriell Institute for Medical Research 403 Haddon Avenue Camden NJ 08103 210672684 501(c)(3) 354062 LRRK2 Cohort Consortium: Coriell Biorepository Supplement Coriell Institute for Medical Research 403 Haddon Avenue Camden NJ 08103 210672684 501(c)(3) 700000 PPMI 2012: BioRepository Funding for 2012-2013 Covance 180 Rustcraft Road Dedham MA 02026 223265977 Public Sector 26480 RE-evaluation of the Qualification samples for DJ-1 Covance 180 Rustcraft Road Dedham MA 02026 223265977 Public Sector 43000 CSF Hemoglobin Assay Covance 180 Rustcraft Road Dedham MA 02026 223265977 Public Sector 65751 PPMI 2012: Covance Funding for Australia Expansion Covance 180 Rustcraft Road Dedham MA 02026 223265977 Public Sector 137500 Covance antibody testing, optimization and assay validation for Full Length LRRK2 P.O.# CAP08192012. DiaLean Ltd 675 US Highway One North Brunswick NJ 08902 Public Sector 205996 DLN-101 for the treatment of Parkinson's Disease DNA 20 1140 OBrien Drive Suite A Menlo Park CA 94025 743076460 Public Sector 9815 LRRK2 HD-Ad5 Duke University CARL Bldg Research Dr Room 487 Durham NC 27710 560532129 501(c)(3) 125000 Targeting beta-arrestin signaling in the treatment of Parkinson's disease East Tennessee State University PO Box 707577 Johnson City TN 37614 626021046 501(c)(3) 74987 A genetic strategy to restore impaired noradrenergic function by increasing expression of noradrenergic phenotypes in the locus coeruleus in Parkinson's disease model mice Eli Lilly & Co Ltd XXXXX XXXXXX Indianapolis IN 46285 350470950 Public Sector 247840 Identification of alpha-synuclein molecular forms correlating with clinicopathology of Parkinson's disease Emerald BioStructures 3 Preston Court Bedford MA 01730 911821586 Public Sector 1343780 LRRK2 Biological Structure and Function Emerald Print Management 1100 University Avenue Suite 142-B Rochester NY 14607 010803249 Public Sector 5894 PPMI 2012: April Label Order #2 Emerald Print Management 1100 University Avenue Suite 142-B Rochester NY 14607 010803249 Public Sector 6785 PPMI 2012: April 2012 Label Order #1 Emory University 1841 Clifton Road Third Floor Atlanta GA 30329 580566256 501(c)(3) 9688 PPMI 2012: rsMRI Ancillary Study Emory University 1841 Clifton Road Third Floor Atlanta GA 30329 580566256 501(c)(3) 14531 PPMI 2012: Cognitive Categorization Ancillary Study Emory University 1510 Clifton Rd Rm 3001 Atlanta GA 30322 580566256 501(c)(3) 25000 Role of PARK18 in Parkinson's Disease Emory University 1841 Clifton Road Third Floor Atlanta GA 30329 580566256 501(c)(3) 155000 PPMI Clinical Trial Site: Year Two Emory University 954 Gatewood Road NE Atlanta GA 30322 580566256 501(c)(3) 250000 Antiparkinsonian effects of T-type calcium channel inhibitors Envoy Therapeutics 555 Heritage Drive Jupiter FL 33458 262535708 Public Sector 1267034 A New Mechanism for Highly Selective Modulation of the Indirect Pathway Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 943409030 Public Sector 6727 Alpha-Synuclein S129 -- IgG cloning and batch production Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 943409030 Public Sector 6727 LRRK1 IgG Cloning & Batch Production Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 943409030 Public Sector 8361 Epitomics Antibodies for LRRK2 ELISA Development by Covance Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 943409030 Public Sector 13454 pLRRK2 -- IgG Cloning Supplement for S955 and S97 3 Antibodies Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 943409030 Public Sector 31802 LRRK2 PS1292 Antiobody Production Epitomics 863 Mitten Road Suite 103 Burlingame CA 94010 943409030 Public Sector 57276 Phospho-Specific Antibody Generation Eureka Genomics 410 Pierce Street Suite 307 Houston TX 77002 261320502 Public Sector 19975 Whole genome sequencing of LRRK2 mouse transgenic lines Feinstein Institute for Medical Research 350 Community Drive Research Build Manhasset NY 11030 112673595 501(c)(3) 578941 Network Biomarkers for the Assessment of Parkinson's Disease: A Multi-modal Optimization Study FPRT Bio Inc PO Box 1335 Winthrop WA 98862 454804420 Public Sector 361700 Peripheral administration of XPro1595 in the rat 6-OHDA model of Parkinson's disease Genentech 1 DNA Way South San Francisco CA 940804990 460500264 Public Sector 292780 Non-human Primate Safety Study of LRRK2 Inhibitors cognitive disorders in Parkinson's disease Harvard University 243 Charles St Boston MA 02115 042103580 501(c)(3) 125000 Non-Invasive Striatal Delivery of Glial Derived Neurotrophic Factor(GDNF) via a Novel Heterotopic Mucosal Grafting Technique Henry Ford Hospital 6777 West Maple Road Detroit MI 48322 381357020 501(c)(3) 147093 Small-molecule PD biomarkers: a metabolomic analysis Indiana University 410 West Tenth Street HS 4000 Indianapolis IN 462023002 356001673 501(c)(3) 7900 Aliquoting and shipping of DATATOP samples Indiana University 410 West Tenth Street HS 4000 Indianapolis IN 462023002 356001673 501(c)(3) 576248 Consortium to Identify LRRK2 Modifiers of Age of Onset Johns Hopkins University 600 N Wolfe Street Meyer 6-119B Baltimore MD 21287 520595110 501(c)(3) 9688 PPMI 2012: rsMRI Ancillary Study Johns Hopkins University 600 N Wolfe Street Meyer 6-119B Baltimore MD 21287 520595110 501(c)(3) 10781 PPMI 2012: Cognitive Categorization Ancillary Study Johns Hopkins University 600 N Wolfe Street Meyer 6-119B Baltimore MD 21287 520595110 501(c)(3) 50000 AV-133: PPMI Ancillary Study KineMed Inc 5980 Horton Street Suite 470 Emeryville CA 94608 912104596 Public Sector 1190319 Cross-sectional examination of cerebrospinal fluid kinetic biomarkers of axonal transport for Parkinson disease diagnosis and progression LZ Therapeutics Inc 490 Lapp Rd Malvern PA 19355 223930731 Public Sector 89480 Evaluation of the Effects of Human Cell Derived GM1 Ganglioside in the MPTP Lesioned Mouse Model of Parkinson's Disease Massachusetts General Hospital 114 16th Street Room 2007 Boston MA 02129 042697983 501(c)(3) 137896 Generation and characterization of iPS neurons from genetic Parkinson's Disease Massachusetts General Hospital Fruit Street WACC 715 Boston MA 02114 042697983 501(c)(3) 212439 Neuroimaging Markers Predict Cognitive Decline in PD Max Planck Florida Institute 5353 Parkside Drive MC19-RE Jupiter FL 334582906 262117502 501(c)(3) 20240 Design of HdAd Type 5 LRRK2 expression vectors Max Planck Florida Institute 5353 Parkside Drive MC19-RE Jupiter FL 334582906 262117502 501(c)(3) 36947 Quality Control of HdAd Type 5 LRRK2 viral vectors Mayo Clinic 13400 E Shea Blvd Scottsdale AZ 85259 593337028 501(c)(3) 15000 Adler compensation for role APDC McLean Hospital 115 Mill St Belmont MA 02478 042697981 501(c)(3) 250000 Does peripheral immune challenge exacerbate LRRK2-induced neuronal pathology? Medical University of South Carolina 326 Calhoun Street Suite 308 Charleston SC 29425 576000722 501(c)(3) 459095 Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease Metabolic Solutions Development Company 161 E Michigan Ave 4th Floor Kalamazoo MI 49007 900736237 Public Sector 210939 Potential of Novel Insulin Sensitizers to Treat Dyskinesia Michigan State University 333 Bostwick Ave NE East Lansing MI 49503 386005984 501(c)(3) 75000 Nigrostriatal alpha-synuclein overexpression in young and aged rats LRRK Michigan State University 333 Bostwick Ave NE East Lansing MI 49503 386005984 501(c)(3) 200000 Alpha-Synuclein Aggregation Leads to Loss of Functional Forms of the Protein and Toxicity. Michigan State University 333 Bostwick Ave NE East Lansing MI 49546 386005984 501(c)(3) 270582 Amitriptyline as a dopamine neuroprotective therapy. NINDS 6001 Executive Blvd Suite 2203 Bethesda MD 20892 520858115 501(c)(3) 100000 iPSC Agreement National Institute on Aging 35 Convent Drive Building 35 Room Bethesda MD 20892 522038294 501(c)(3) 122165 Non-kinase targets in LRRK2 biology Neuroscience Associates 10915 Lake Ridge Drive Knoxville TN 379344919 621540123 Public Sector 68610 Pathological Characterization of Wildtype Rats as a controls for CJ LRRK2 Rats Neuroscience Associates 10915 Lake Ridge Drive Knoxville TN 379344919 621540123 Public Sector 172633 Pathological characterization of aged KO rats Neuroscience Associates 10915 Lake Ridge Drive Knoxville TN 379344919 621540123 Public Sector 245874 Pathological Characterization of aSyn mouse models New York Institute of Technology Northern Boulevard Riland Building Old Westbury NY 115688000 111788788 501(c)(3) 75000 The Effects of Tyrosine on Orthostatic Hypotension in Parkinson's Disease Northwestern University 710 North Lake Shore Drive 1425 A Chicago IL 60611 362167817 501(c)(3) 9688 PPMI 2012: rsMRI Ancillary Study Northwestern University 710 North Lake Shore Drive 1425 A Chicago IL 60611 362167817 501(c)(3) 16406 PPMI 2012: Cognitive Categorization Ancillary Study Northwestern University 710 North Lake Shore Drive 1425 A Chicago IL 60611 362167817 501(c)(3) 28534 PPMI 2012: Steering Committee Support for Tanya Simuni Northwestern University 710 North Lake Shore Drive 1425 A Chicago IL 60611 362167817 501(c)(3) 112500 PPMI 2012: Consulting Support for rsMRI Sub- study (2012-2015) Northwestern University 710 North Lake Shore Drive 1425 A Chicago IL 60611 362167817 501(c)(3) 186250 PPMI Clinical Trial Site: Year Two Octagon Research Solutions Inc 585 E Swedesford Road Suite 200 Wayne PA 19087 233022539 Public Sector 38000 eCTD IND Submission for the AVE8112 MAD study Oregon Health & Science University 3181 SW Sam Jackson Park Rd OP-32 Portland OR 97239 931176109 501(c)(3) 15938 PPMI 2012: Cognitive Categorization Ancillary Study Oregon Health & Science University 3181 SW Sam Jackson Park Road Portland OR 97239 931176109 501(c)(3) 30000 Investigation of possible pathological changes in aged LRRK2 knockout rats Parexel 1560 Chevy Chase Drive Suite 140 Glendale CA 91206 043517643 Public Sector 211800 Parexel Regulatory Services-Sanofi Trial Parexel 1560 Chevy Chase Drive Suite 140 Glendale CA 91206 043517643 Public Sector 1116184 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients with Parkinson's Disease Parkinson's Action Network 1025 Vermont Ave NW Suite 1120 Washington DC 20005 943172675 501(c)(3) 250000 PAN Funding 2012 Parkinson's Disease and Movement Disorder C 951 NW 13th Street Bldg 5-E Boca Raton FL 33486 223659456 501(c)(3) 14063 PPMI 2012: Cognitive Categorization Ancillary Study Pfizer Global Research and Development Eastern Point Road Groton CT 06340 141396954 Public Sector 216934 LRRK2 PET Tracer Development Promentis Pharmaceuticals 826 N Plankinton Ave Suite 4000 Milwaukee WI 80021 753234358 Public Sector 299384 Targeting System-xc for the Treatment of Parkinson's Disease Proteos 4717 Campus Drive Kalamazoo MI 49008 260069252 Public Sector 31003 Asyn Filament Antibody Proteos 4717 Campus Drive Kalamazoo MI 49008 260069252 Public Sector 69311 Post-Translationally Modified Alpha-Synuclein: Generation of Alpha-Synuclein Protein PsychoGenics 765 Old Saw Mill River Road Suite Tarrytown NY 10591 134034631 Public Sector 206000 Supplement to Phenotyping assessment of a DJ1 and Pink1 KO rats for PD Purdue University 550 Stadium Mall Dr West Lafayette IN 47907 356002041 501(c)(3) 250000 Parkinson's and inflammatory bowel diseases: interaction in LRRK2 transgenic rats QR Pharma 1055 Westlakes Drive Suite 300 Berwyn PA 19312 262540421 Public Sector 468640 Development of Posiphen to treat Parkinson's Disease Rush University 1735 West Harrison Street Suite 30 Chicago IL 60612 362174823 501(c)(3) 31250 Rush University Tissue Resource Rush University 1725 W Harrison St Suite 755 Chicago IL 60612 362174823 501(c)(3) 111875 BioFIND Clinical Trial Site: Rush University Rush University 1735 West Harrison Street Suite 30 Chicago IL 60612 362174823 501(c)(3) 491803 The transfer of alpha-synuclein: Mechanistic and therapeutic studies Rush University 1725 W Harrison Suite 755 Chicago IL 60612 362174823 501(c)(3) 1007721 TOPIRAMATE AS AN ADJUNCT TO AMANTADINE IN THE TREATMENT OF DYSKINESIA IN PARKINSON'S Disease Sanford-Burnham Institute for Medical Research 10901 N Torrey Pines Rd La Jolla CA 92037 510197108 501(c)(3) 124320 Protein S-Nitrosylation as a Potential Biomarker for Parkinson's Disease Sensonics Inc PO Box 112 Haddon Heights NJ 08035 232225611 Public Sector 25710 PPMI 2012: 1st Batch Order of UPSITS for Prodromal PPMI (P-PPMI) - Dec 2012 Sigma-Aldrich 2033 Westport Center Drive St Louis MO 63146 841656258 Public Sector 6496 Sage LRRK2 KO Rat Pathology Study Sigma-Aldrich 1140 OBrien Drive suite A Menlo Park CA 94025 841656258 Public Sector 204538 Sigma-Cell Lines Southern Research Institute 2000 Ninth Ave South Birmingham AL 35205 630288868 501(c)(3) 59956 VILIP-1 as diagnostic and prognostic biomarker for Parkinson's Disease Stanford University 300 Pasteur Drive Room H3160 Stanford CA 94305 941156365 501(c)(3) 237525 Small molecule ligand for TrkB/TrkC as a novel therapeutic for Parkinson's Disease Stanford University 1201 Welch Rd MSLS Building P304 Stanford CA 943055487 941156365 501(c)(3) 249896 The Four Horsemen of G2019S State University of New York at Binghamton 4400 Vestal Parkway East Science 4 Binghamton NY 13902 141368361 501(c)(3) 74944 Potential of concomitant targeting of 5-HT1A and 5-HT2A receptors against L-DOPA induced dyskinesia in the hemi-parkinsonian rat model SUNY Downstate Medical Center 450 Clarkson Ave Brooklyn NY 11203 141368361 501(c)(3) 311521 Intrinsic Remodeling of the Fovea in Parkinson's Disease Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 Public Sector 55162 Breeding and aging of aSyn mouse models at Taconic Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 Public Sector 55399 Breeding and Aging of SD Wildtype Littermate Rats as controls for CJ Li LRRK2 Rats Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 Public Sector 80363 Housing of CJ Li-generated BAC LRRK2 rats at Taconic Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 Public Sector 100000 Taconic additional housing and breeding supplement Taconic 5 Cedar Brook Drive Cranbury NJ 08512 330675808 Public Sector 174051 Housing of CJ Li-generated BAC alpha-synuclein rats at Taconic Texas A&M University Department of Pathobiology 218 VMA College Station TX 77843 742245072 501(c)(3) 150000 The role of alpha-synuclein in the pathogenesis of Parkinson's disease in a rat model- SUPPLEMENT The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06511 061582206 501(c)(3) 6000 PPMI Data Entry for Q1 2012 The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B NEW HAVEN CT 06511 061582206 501(c)(3) 7500 PPMI Data Entry for Q2 2012 The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06511 061582206 501(c)(3) 7500 PPMI Data Entry for Q3 2012 The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06511 061582206 501(c)(3) 22969 PPMI 2012: Cognitive Categorization Ancillary Study The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 23750 PPMI 2012: Leadership Core Support for AV133 Sub Study The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06511 061582206 501(c)(3) 50000 AV-133: PPMI Ancillary Study The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 60000 PPMI 2012: Leadership Core Support for P-PPMI The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 114000 PPMI 2012: Imaging Core Support for rsMRI Sub study The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 166667 PPMI 2012: 2013 Imaging Core Support for P-PPMI (LRRK2) The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 176250 PPMI 2012: Imaging Core Support for AV133 Sub study The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 333333 PPMI 2012: 2013 Imaging Core Support for P-PPMI The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06511 061582206 501(c)(3) 350000 PPMI 2012: Olfactory Core Support The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 352678 PPMI 2012: Leadership Core Year 3 Funding Support The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 500000 PPMI 2012: Site Support for Prodromal PPMI (P-PPMI) through Leadership Core - Dec 2012 The Institute for Neurodegenerative Disorders 60 Temple St Suite 8B New Haven CT 06510 061582206 501(c)(3) 621284 PPMI 2012: Imaging Core - Year 3 Funding Support The Jackson Laboratory 610 Main Street Bar Harbor ME 04609 010211513 501(c)(3) 7000 GBA knockin mouse rederivation and housing The Jackson Laboratory 600 Main Street Bar Harbor ME 04609 010211513 501(c)(3) 96591 Breeding and aging of aSyn mouse models at JAX The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 10781 PPMI 2012: Cognitive Categorization Ancillary Study The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 36632 PPMI 2012: 2012 Steering Committee Support for Carolline Tanner The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94089 943061594 501(c)(3) 51984 Assessing Heart Rate Variability (HRV) in the Parkinson's Associated Risk Study (PARS) Cohort - Part 2 The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94089 943061594 501(c)(3) 100000 2012 Pritzker Prize - winner The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 138996 The effects of memantine on L-DOPA induced dyskinesias in MPTP-treated squirrel monkeys The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 229406 PPMI Clinical Trial Site: Year Two The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 249764 Establishing LRRK2 Signaling Pathways The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 278444 Combined therapy with amantadine and fenobam for L-DOPA induced dyskinesias in MPTP- treated squirrel monkeys The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 411020 Bay Area Solvent Study - Symptoms (BASS-S) The Parkinson's Institute 675 Almanor Avenue Sunnyvale CA 94085 943061594 501(c)(3) 475375 Parkinson's Institute LRRK2 cohort: clinical phenotype, pre/non-motor and environmental risk assessment The Salk Institute for Biological Studies 10010 N Torrey Pines Road La Jolla CA 920371099 952160097 501(c)(3) 75000 A Pair of Neurotrophic Factor Inducing Drug Candidates Thomas Jefferson University 1020 Locust Street 521 JAH Philadelphia PA 19107 232829095 501(c)(3) 74967 Enzymatic Degradation of Brain Complex Gangliosides to Increase Endogenous GM1 Levels: Potential Neuroprotective/ Neurorestorative Therapy For Parkinson's Disease Thomas Jefferson University 900 Walnut Street-JHN Suite 462 Philadelphia PA 19107 232829095 501(c)(3) 114618 Characterization of the hTH-GFP rat Thomas Jefferson University 900 Walnut Street-JHN Suite 462 Philadelphia PA 19107 232829095 501(c)(3) 139380 Gremlin-1 a putative VTA-derived Neuroprotective Factor in Parkinson's disease Thomson Reuters 169 Saxony Road Suite 104 Encinitas CA 92024 231569117 Public Sector 19000 Grant Outcomes Analysis University of Alabama at Birmingham 1719 6th Ave South CIRC 516 Birmingham AL 352940021 636005396 501(c)(3) 15469 PPMI 2012: Cognitive Categorization Ancillary Study University of Alabama at Birmingham 1530 3rd Avenue South Birmingham AL 352941150 636005396 501(c)(3) 125047 Targeting the JAK/STAT Pathway in the Treatment of Parkinson's Disease University of Alabama at Birmingham 1719 6th Ave S CIRC 516 Birmingham AL 35294 636005396 501(c)(3) 200000 Role of LRRK2 in alpha-synuclein-induced neurodegeneration University of Arizona 1501 N Campbell Ave PO Box 2450 Tucson AZ 857245023 742652689 501(c)(3) 75000 Opioid glycopeptides for the treatment of levodopa-induced dyskinesias University of California Berkeley 127 Morgan Hall Berkeley CA 94720 946002123 501(c)(3) 250000 Monoacylglycerol Lipase as a Novel Target for Combatting Parkinson's Disease University of California Los Angeles 635 Charles E Young Drive South Los Angeles CA 900957334 956006143 501(c)(3) 14583 PPMI 2012: Bioinformatics Core Support for Prodromal PPMI (P-PPMI) in 2013 - LRRK2 Contribution University of California Los Angeles 635 Charles E Young Drive South S Los Angeles CA 900957334 956006143 501(c)(3) 29167 PPMI 2012: Support for Bioinformatics Core for Prodromal PPMI (P-PPMI) in 2013 University of California Los Angeles 635 Charles E Young Drive South S Los Angeles CA 900957334 956006143 501(c)(3) 33750 PPMI 2012: Bioinformatics Core Support for rsMRI Sub study University of California Los Angeles 635 Charles E Young Drive South S Los Angeles CA 900957334 956006143 501(c)(3) 49375 PPMI2012: Bioinformatics Core Support for AV 133 Sub study University of California Los Angeles 635 Charles E Young Drive South S Los Angeles CA 900957334 956006143 501(c)(3) 53750 PPMI 2012: Bioinformatics Core Support for Cognitive Categorization Ancillary Study University of California Los Angeles 635 Charles E Young Drive South S Los Angeles CA 900957334 956006143 501(c)(3) 315928 PPMI 2012: Bioinformatics Core Year 3 Funding Support University of California San Diego 9500 Gilman Drive 0662 San Diego CA 920930662 952544535 501(c)(3) 7031 PPMI 2012: Cognitive Categorization Ancillary Study University of California San Francisco 4150 Clement St 114M San Francisco CA 94121 946036493 501(c)(3) 97961 PPMI 2012: Year 3 Funding Support for DTI Core University of California San Francisco 1650 Owens Street San Francisco CA 94158 946036493 501(c)(3) 200000 Normal role of synuclein in mitochondrial bioenergetics at the synapse University of California San Francisco 1855 Folsom St Box 555 MCB Room San Francisco CA 94103 946036493 501(c)(3) 2036664 A Phase 1 Bridging Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) Administered by MRI-Guided Real-Time Convective Infusion in the Putamen of Subjects with Parkinson's Disease University of Chicago 5841 S Maryland Avenue MC 2030 Chicago IL 60637 362177139 501(c)(3) 48202 A Small Molecule Approach to Correct Striatal Cholinergic Interneuron Dysfunction University of Chicago 924 East 57th Street Knapp Center Chicago IL 60637 362177139 501(c)(3) 75000 Reversing pre-existing pathologies of DA neurons in a novel inducible human alpha- synuclein transgenic mouse model. University of Chicago 5841 S Maryland Avenue MC 2030 Chicago IL 60637 362177139 501(c)(3) 95829 BioFIND- Oversite PI award University of Chicago 5841 S Maryland Ave MC2030 Room Chicago IL 60637 362177139 501(c)(3) 111875 BioFIND Clinical Trial Site: University of Chicago University of Cincinnati 260 Stetson St Suite 2300 Cincinnati OH 45267 316000989 501(c)(3) 14063 PPMI 2012: Cognitive Categorization Ancillary Study University of Cincinnati 3225 Eden Ave 136 HPB Cincinnati OH 45267 316000989 501(c)(3) 74999 THE MIFUNCTIONAL CEMBRANOIDS FOR THERAPY OF PARKINSON'S DISEASE University of Cincinnati 260 Stetson St Suite 2300 Cincinnati OH 45267 316000989 501(c)(3) 326969 PPMI Clinical Trial Site University of Colorado Denver 12850 E Montview Blvd Mail Stop Aurora CO 800452605 846000555 501(c)(3) 415151 Optimizing Glyoxylate Metalloporphryins for Clinical Development in Parkinson's disease: Evaluation in the Rat 6OHDA Model University of Florida 100 S Newell Dr Room L1-100A Gainesville FL 32610 596002052 501(c)(3) 79482 In Vivo Characterization of Helper-Dependent Adenoviral Vectors Expressing Human LRRK2 University of Florida 100 S Newell Dr Room L1-100A Gainesville FL 32610 596002052 501(c)(3) 273186 Development of appropriate control transgenes for long term viral vector mediated gene transfer and optical imaging in the Nigra University of Iowa 2450 University Capitol Center Iowa City IA 52242 426004813 501(c)(3) 9167 PPMI 2012: 2013 Statistics Core Support for P-PPMI (LRRK2) University of Iowa 2450 University Capitol Center Iowa City IA 52242 426004813 501(c)(3) 18333 PPMI 2012: 2013 Statistics Core Support for P-PPMI University of Iowa 2450 University Capitol Center Iowa City IA 52242 426004813 501(c)(3) 215426 PPMI 2012: Statistics Core Year 3 Funding Report University of Michigan 1500 East Medical Center Drive Ann Arbor MI 481090028 386006309 501(c)(3) 1000000 The Role of A-beta in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study University of Minnesota 516 Delaware St SE 12-146 P W B Minneapolis MN 55455 416007513 501(c)(3) 116775 BioFIND Clinical Trial Site: University of Minnesota University of North Carolina at Chapel Hill 101 Manning Drive Chapel Hill NC 27599 566001393 501(c)(3) 6579 HD-AD5 UNC SMALL BATCH/ DISTRIBUTION University of Pennsylvania 330 South 9th Street Philadelphia PA 19104 231352685 501(c)(3) 13594 PPMI 2012: Cognitive Categorization Ancillary Study University of Pennsylvania 330 South 9th Street Philadelphia PA 19107 231352685 501(c)(3) 28813 PPMI 2012: 2012 Steering Committee Support for Andrew Siderowf University of Pennsylvania 125 S 31st Street Philadelphia PA 19104 231352685 501(c)(3) 30122 PPMI: Support for Ethics Component of Prodromal Study University of Pennsylvania 330 South 9th Street Philadelphia PA 19104 231352685 501(c)(3) 50000 AV-133: PPMI Ancillary Study University of Pennsylvania 3600 Spruce St Maloney Bldg 3rd Philadelphia PA 19104 231352685 501(c)(3) 124984 Evaluation of the Microtubule-Stabilizing Agent, Epothilone D, in Mouse Models of Parkinson's Disease University of Pennsylvania 330 South 9th Street Philadelphia PA 19104 231352685 501(c)(3) 147500 PPMI Clinical Trial Site: Year Two University of Pennsylvania 3400 Spruce Street 7103 Founders Philadelphia PA 19104 231352685 501(c)(3) 300134 PPMI 2012: Year 3 Funding Support for Bioanalytics Core University of Rochester 919 Westfall Road Building C Suit Rochester MI 14618 263800000 501(c)(3) 11719 PPMI 2012: Cognitive Categorization Ancillary Study University of Rochester 265 Crittenden Blvd Rochester NY 14620 263800000 501(c)(3) 13500 Datatop Samples Statistical Support from CHET, University of Rochester- Supplement University of Rochester 265 Crittenden Blvd Rochester NY 14620 263800000 501(c)(3) 15938 Datatop Samples Statistical Support from CHET, University of Rochester University of Rochester 919 Westfall Road Building C Suit Rochester NY 14618 263800000 501(c)(3) 224500 PPMI Clinical Trial Site: Year 2 University of Rochester 265 Crittenden Blvd Rochester NY 14620 263800000 501(c)(3) 335000 CTCC-PI for Discovery Cohort University of Rochester 1351 Mt Hope Avenue Suite 216 Rochester NY 14620 263800000 501(c)(3) 852238 PPMI 2012: Year 3 Funding Support for the PPMI Clinical Core University of South Florida 4001 East Fletcher Avenue 6th Floo Tampa FL 33613 593102112 501(c)(3) 16875 PPMI 2012: Cognitive Categorization Ancillary Study University of South Florida 4001 East Fletcher Avenue 6th Floo Tampa FL 33613 593102112 501(c)(3) 173750 PPMI Clinical Trial Site: Year Two University of Texas Health Science Center San An 7703 Floyd Curl Drive San Antonio TX 78229 741586031 501(c)(3) 125000 Novel cell-based strategy for GDNF delivery in Parkinson's disease University of Washington 1660 S Columbian Way VA-PSHCS 11 Seattle WA 98108 916001537 501(c)(3) 15469 PPMI 2012: Cognitive Categorization Ancillary Study University of Washington 300 9th Ave RT Room 321 Seattle WA 98124 916001537 501(c)(3) 74892 Phosphorylated alpha-synuclein species as biomarkers for diagnosis and progression in Parkinson's disease University of Washington 1660 S Columbian Way VA-PSHCS 11 Seattle WA 98108 916001537 501(c)(3) 170000 PPMI Clinical Trial Site: Year Two UT Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Mail Code 88 Dallas TX 753908813 756002868 501(c)(3) 43915 Analysis of archived tissue from Parkin, DJ-1, PINK1 and LRRK2 KO rats UT Southwestern Medical Center at Dallas 5323 Harry Hines Blvd Mail Code 88 Dallas TX 753908813 756002868 501(c)(3) 275000 Mechanisms of cellular regulation and post- translational modification of LRRK2 Van Andel Research Institute 333 Bostwick Avenue NE Grand Rapids MI 49503 522000823 501(c)(3) 99779 Circulating microRNAs: a new paradigm for Parkinson's disease biomarker discovery Vanderbilt University PHV Suite 313 1601 23rd Ave Sout Nashville TN 37212 620476822 501(c)(3) 98894 Preferential loss of serotonin axon subtypes in depression in Parkinson's Disease Virginia College of Osteopathic Medicine 1861 Pratt Drive Corp Res Ctr - Blacksburg VA 24060 542052107 501(c)(3) 189519 Cerium Oxide Nanoparticles in the Treatment of Parkinson's Disease - Toxicity & Biodistribution Studies Virginia Commonwealth University PO Box 980539 Richmond VA 55905 546001758 501(c)(3) 107492 A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson's Disease Washington State University Pullman Dept VCAPP Pullman WA 991646520 916001108 501(c)(3) 74999 Development of Small Molecule Hepatocyte Growth Factor Mimetics for the Treatment of Parkinson's Disease Washington University in St Louis 510 S Kingshighway Blvd St Louis MO 63110 430653611 501(c)(3) 200000 Alpha Synuclein Autoradiography Core Weill Medical College of Cornell University 428 East 72nd Street Suite 400 New York NY 10021 131623978 501(c)(3) 111875 BioFIND Clinical Trial Site: Cornell University WIL Research Laboratories 1407 George Road Ashland OH 448058946 260564612 Public Sector 25500 Collection and storage of rodent brain and peripheral tissues- Supplement WIL Research Laboratories 1407 George Road Ashland OH 448058946 260564612 Public Sector 63000 Phenotypic Characterization of Wildtype Rats as a controls for CJ LRRK2 Rats WIL Research Laboratories 1407 George Road Ashland OH 448058946 260564612 Public Sector 142500 SAGE LRRK2 KO RAT PATHOLOGY STUDY WIL Research Laboratories 1407 George Road Ashland OH 448058946 260564612 Public Sector 315000 Behavioral Characterization of aSyn mouse models World Parkinson Coalition Inc 1359 Broadway Suite 1509 New York NY 10018 571206493 501(c)(3) 51555 3rd World Parkinson Congress (WPC 2013) XenoPort 3410 Central Expressway Santa Clara CA 95051 943330837 Public Sector 347075 Novel Fumarate Esters as Neuroprotective Agents in Parkinson's Disease 167 55 SCHEDULE I, PART I, LINE 2 PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES: THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made. X X X X false false false false false false false false false Todd Sherer 280616 0 165000 0 0 0 7500 0 18590 0 471706 0 0 0 Joanne Martz 215473 0 80000 0 0 0 7500 0 12548 0 315521 0 0 0 Deborah W Brooks 300660 0 210000 0 0 0 7500 0 18590 0 536750 0 0 0 Sohini Chowdhury 180396 0 30000 0 0 0 6312 0 6140 0 222848 0 0 0 Sheila Kelly 165363 0 19500 0 0 0 5546 0 6139 0 196548 0 0 0 Holly Teichholtz 130286 0 15000 0 0 0 4359 0 12548 0 162193 0 0 0 Brian K Fiske 169200 0 17500 0 0 0 5387 0 12548 0 204635 0 0 0 Mark A Frasier 160352 0 17500 0 0 0 5335 0 0 0 183187 0 0 0 Alison Urkowitz 132290 0 13000 0 0 0 4359 0 6140 0 155789 0 0 0 Laxmi Wordham 200440 0 30000 0 0 0 6913 0 18590 0 255943 0 0 0 DETERMINATION OF COMPENSATION FOR OFFICERS SCHEDULE J, PART I, QUESTION 3 Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. X 57 33493293 FAIR VALUE false true false FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1 FINDING THE CURE FOR PARKINSONS TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. Actor Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research (the "Foundation"), incorporated in Delaware in 2000, after publicly disclosing in 1998 that he had been diagnosed with Parkinson's disease seven years earlier, at age 29. In 2009, The Michael J. Fox Foundation for Parkinson's Research in Canada ("MJFF Canada") was established as an officially registered tax-exempt charity in Canada. As this entity meets the criteria for consolidation, its financial statements are consolidated with those of the Foundation. As MJFF Canada's assets and liabilities and its operations were not significant at December 31, 2012 and 2011, they are not shown separately in the accompanying consolidated financial statements. The Foundation is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code, and from state and local taxes under comparable laws. MJFF Canada is exempt from similar taxes under Canadian law. Today, The Michael J. Fox Foundation is the world's largest private funder of Parkinson's research. It is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $344 million in research as of December 31, 2012, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. In addition to funding a broad portfolio of investigator-initiated and priority-driven research programs, the Foundation is working to transform the medical research enterprise and shape a system that fosters, rather than inhibits, the development of cures. MJFF partners with the Parkinson's research community, speeding financial and intellectual resources to the scientists who can help realize ideas with the greatest promise to impact patients' lives. The Foundation has ignited collaboration among academic and industry players by requiring researchers to share information in real time. To enable scientists to move toward breakthroughs faster, MJFF has stepped up to meet their need for research tools. To date, the Foundation has funded work on over 100 therapeutic targets, and is supporting 60 clinical trials. Since its founding, MJFF has proven not only that a new kind of stakeholder can accelerate drug development - but that it is what was missing all along. While much has changed in the past decade, one thing remains constant: the Foundation's commitment to Parkinson's patients. Everything MJFF does is with patients in mind, at all stages of PD, which informs investments in disease-modifying therapies, better symptomatic treatments and new approaches to the symptoms entirely unaddressed by today's generation of drugs. Form 990, Page 6 Governance, Management and Disclosure Line 2: BOARD MEMBER RELATIONSHIPS TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 4: BY-LAW CHANGES DURING 2012, THE FOUNDATION REVISED ITS BY-LAWS. SIGNIFICANT CHANGES INCLUDE AN INCREASE IN THE MAXIMUM NUMBER OF DIRECTORS FROM 30 TO 50. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: CONFLICT OF INTEREST POLICY Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the Chief Financial and Administrative Officer, and conflicts are reviewed with the Board of Directors. Line 15: PROCESS FOR DETERMINING COMPENSATION Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org. MJFF CANADA 365 Bay Street Suite 899 Toronto Ontario CA RESEARCH CA MJFF (US) false false false true false false false false false false false false false false false false false false false THE MICHAEL J FOX FOUNDATION (CANADA) C 293559 FMV